The aim is to determine if a protein-based signature can effectively stratify intermediate-risk prostate cancer patients' risk of recurrence.
Utilized proteomic analysis to identify protein signatures in prostate cancer patients.
Focused on patients with Gleason grade groups 2 and 3.
Employed statistical methods to assess the predictive power of the identified protein signatures.
Identified a specific protein signature linked to the risk of biochemical recurrence.
The signature demonstrated a strong ability to differentiate between low and high-risk patients.
Abstract
This study demonstrates the ability of a protein-based signature to risk-stratify prostate cancer patients with Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence.